Syngene International Ltd (SYNGENE) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Syngene returned to growth in Q3 FY25, reporting an 11% year-on-year increase in revenue from operations, reaching Rs. 944 crores. A favorable exchange rate contributed approximately 8% to this growth, with 3% attributed to constant currency growth.
- Sequential revenue growth from Q2 to Q3 FY25 was 6%, indicating positive momentum.
- Operating EBITDA increased by 23% to Rs. 284 crores, leading to an improved operating EBITDA margin of 30.1%, up 300 basis points year-on-year.
- Profit after tax (PAT) after exceptional items rose by 18% to Rs. 131 crores, driven by strong underlying performance.
- While the US biotech funding environment showed signs of stabilization, the recovery was slower than initially anticipated, impacting the timing of growth but not the overall positive trajectory.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.